AAAAAA

   
Results: 1-9 |
Results: 9
EFFECTS OF PALA ON THE PHARMACOKINETICS OF 5-FLUOROURACIL
Authors: NASSIM M ROUINI MR CRIPPS MC SHIRAZI FH VEERASINGHAN S MOLEPO JM OBROCEA M REDMOND D BATES S FRY D STEWART DJ GOEL R
Citation: M. Nassim et al., EFFECTS OF PALA ON THE PHARMACOKINETICS OF 5-FLUOROURACIL, Oncology Reports, 5(1), 1998, pp. 217-221
CONCURRENT USE OF MULTIPLE CHEMOTHERAPY RESISTANCE MODULATORS WITH ETOPOSIDE IN PATIENTS WITH RESISTANT MALIGNANCIES
Authors: STEWART DJ GOEL R CRIPPS MC YAU J HUAN S TOMIAK E DAVIES RA DULUDE H GALLANT G
Citation: Dj. Stewart et al., CONCURRENT USE OF MULTIPLE CHEMOTHERAPY RESISTANCE MODULATORS WITH ETOPOSIDE IN PATIENTS WITH RESISTANT MALIGNANCIES, International journal of oncology, 11(4), 1997, pp. 709-716
PHASE-II STUDY OF A MULTITARGETED ANTIFOLATE (LY231514) (MTA) AS FIRST LINE THERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC COLORECTAL-CANCER (MCC)
Authors: CRIPPS MC BURNELL M JOLIVET J LOFTERS W FISHER B PANASCI L IGLESIAS J EISENHAUER E
Citation: Mc. Cripps et al., PHASE-II STUDY OF A MULTITARGETED ANTIFOLATE (LY231514) (MTA) AS FIRST LINE THERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC COLORECTAL-CANCER (MCC), European journal of cancer, 33, 1997, pp. 768-768
IMPROVEMENTS IN SURVIVAL AND CLINICAL BENEFIT WITH GEMCITABINE AS FIRST-LINE THERAPY FOR PATIENTS WITH ADVANCED PANCREAS CANCER - A RANDOMIZED TRIAL
Authors: BURRIS HA MOORE MJ ANDERSEN J GREEN MR ROTHENBERG ML MADIANO MR CRIPPS MC PORTENOY RK STORNIOLO AM TARASSOFF P NELSON R DORR FA STEPHENS CD VANHOFF DD
Citation: Ha. Burris et al., IMPROVEMENTS IN SURVIVAL AND CLINICAL BENEFIT WITH GEMCITABINE AS FIRST-LINE THERAPY FOR PATIENTS WITH ADVANCED PANCREAS CANCER - A RANDOMIZED TRIAL, Journal of clinical oncology, 15(6), 1997, pp. 2403-2413
PILOT-STUDY OF MULTIPLE CHEMOTHERAPY RESISTANCE MODULATORS PLUS EPIRUBICIN IN THE TREATMENT OF RESISTANT MALIGNANCIES
Authors: STEWART DJ CRIPPS MC GOEL R DAHROUGE S YAU J TOMIAK E HUAN S SOLTYS K PROSSER A DAVIES RA
Citation: Dj. Stewart et al., PILOT-STUDY OF MULTIPLE CHEMOTHERAPY RESISTANCE MODULATORS PLUS EPIRUBICIN IN THE TREATMENT OF RESISTANT MALIGNANCIES, Cancer chemotherapy and pharmacology, 41(1), 1997, pp. 1-8
MULTIPLE RESISTANCE MODULATORS COMBINED WITH CARBOPLATIN FOR RESISTANT MALIGNANCIES - A PILOT-STUDY
Authors: STEWART DJ GOEL R CRIPPS MC HUAN S YAU J VERMA S
Citation: Dj. Stewart et al., MULTIPLE RESISTANCE MODULATORS COMBINED WITH CARBOPLATIN FOR RESISTANT MALIGNANCIES - A PILOT-STUDY, Investigational new drugs, 15(4), 1997, pp. 267-277
A PHASE-II TRIAL OF GEMCITABINE IN PATIENTS WITH 5-FU-REFRACTORY PANCREAS CANCER
Authors: ROTHENBERG ML MOORE MJ CRIPPS MC ANDERSEN JS PORTENOY RK BURRIS HA GREEN MR TARASSOFF PG BROWN TD CASPER ES STORNIOLO AM VONHOFF DD ALBERTS DS WOLFF R KELSEN DP KOCHA W HALLER DG MODIANOREVAH M MOORE M OKEN MM SCHILSKY RL SHAH A
Citation: Ml. Rothenberg et al., A PHASE-II TRIAL OF GEMCITABINE IN PATIENTS WITH 5-FU-REFRACTORY PANCREAS CANCER, Annals of oncology, 7(4), 1996, pp. 347-353
DURATION OF INTRAVENOUS ANTIBIOTICS FOR PATIENTS WITH NEUTROPENIC FEVER
Authors: TOMIAK AT YAU JC HUAN SD CRIPPS MC GOEL R PERRAULT DJ BOURCIER JD PROSSER IA SOLTYS KM EVANS WK STEWART DJ
Citation: At. Tomiak et al., DURATION OF INTRAVENOUS ANTIBIOTICS FOR PATIENTS WITH NEUTROPENIC FEVER, Annals of oncology, 5(5), 1994, pp. 441-445
ESCALATED AS COMPARED WITH STANDARD DOSES OF DOXORUBICIN IN BACOP THERAPY FOR PATIENTS WITH NON-HODGKINS-LYMPHOMA
Authors: MEYER RM QUIRT IC SKILLINGS JR CRIPPS MC BRAMWELL VHC WEINERMAN BH GOSPODAROWICZ MK BURNS BF SARGEANT AM SHEPHERD LE ZEE B HRYNIUK WM
Citation: Rm. Meyer et al., ESCALATED AS COMPARED WITH STANDARD DOSES OF DOXORUBICIN IN BACOP THERAPY FOR PATIENTS WITH NON-HODGKINS-LYMPHOMA, The New England journal of medicine, 329(24), 1993, pp. 1770-1776
Risultati: 1-9 |